Latest News

Category: ASX

See all

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

ASX, Clinical, News,

Telix today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga (gallium)-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating PET imaging for...

Read more

Telix Submits NDA for New Prostate Cancer Imaging Agent 

ASX, News,

Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”)...

Read more

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

ASX, News,

Telix today announces the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate...

Read more

Telix Completes Acquisition of QSAM Biosciences and Its Bone Cancer Targeting Platform

ASX, News,

Telix today announces the completion of the acquisition of QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company...

Read more

Notice of Annual General Meeting 2024

ASX, News,

Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 22 May...

Read more

Q1 2024 Revenue and Business Update 

ASX, News,

Telix today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1...

Read more

Telix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform 

ASX, News,

Telix, today announces the completion of the acquisition of radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals...

Read more

Telix Completes Acquisition of IsoTherapeutics

ASX, Events, News,

Telix today announces the completion of the acquisition of IsoTherapeutics.   IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in...

Read more

Telix GM 2024

ASX, Events, News,

Telix's 2024 GM was held on Friday, 5th April 2024 at The Wesley Conference Centre in Sydney, Australia and...

Read more

Appointment of Dr Darren Patti to Group Chief Operating Officer

ASX,

Telix is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March...

Read more